Adaptation and validation of the Spanish version of the Patient-Oriented Prostate Utility Scale (PORPUS) |
| |
Authors: | Mónica Ávila Yolanda Pardo Manel Castells Ferran Ferrer Ana Boladeras Joan Pera Pedro J. Prada Benjamin Guix Belen de Paula Helena Hernandez Angels Pont Jordi Alonso Olatz Garin Karen Bremner Murray Krahn Montse Ferrer The Multicentric Spanish Group of Clinically Localized Prostate Cancer |
| |
Affiliation: | 1. Health Services Research Unit, IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain 2. CIBER en Epidemiología y Salud Pública, CIBERESP http://www.ciberesp.es/ 3. Universitat Pompeu Fabra, Barcelona, Spain 4. Universitat Autònoma de Barcelona, Bellaterra, Spain 5. Hospital Universitari de Bellvitge, Barcelona, Spain 6. Institut Català d’Oncologia, Barcelona, Spain 7. Hospital Universitario Central de Asturias, Oviedo, Spain 8. Fundación IMOR, Barcelona, Spain 9. Instituto Oncológico de Guipúzcoa, San Sebastián, Spain 10. Hospital Meixoeiro-Complejo CHUVI, Vigo, Spain 11. Toronto General Hospital, University Health Network, Toronto, Canada
|
| |
Abstract: | Objective The Patient-Oriented Prostate Utility Scale (PORPUS) is a combined profile and utility-based quality of life measure for prostate cancer patients. Our objectives were to adapt the PORPUS into Spanish and to assess its acceptability, reliability, and validity. Methods The PORPUS was adapted into Spanish using forward and back translations and cognitive debriefing. PORPUS was administered jointly with the SF-36 and the Expanded Prostate Index Composite (EPIC) to 480 Spanish prostate cancer patients treated with radical prostatectomy or radiotherapy. The Spanish PORPUS scores’ distribution and reliability were examined and compared with the original instrument. To evaluate construct validity, relationships were assessed between PORPUS and other instruments (testing hypotheses of the original PORPUS study), and among known groups defined by side effect severity. Results Reliability coefficient was 0.76 (similar to the original PORPUS’ 0.81). Spanish PORPUS items presented correlations ranging 0.57–0.88 with the corresponding EPIC domains, as in the original PORPUS study (0.60–0.83). Both PORPUS-P and PORPUS-U showed significant differences and large effect sizes (0.94–1.90) when comparing severe versus no problem groups on urinary, bowel, sexual and hormonal side effects defined by EPIC. Conclusions A conceptually equivalent Spanish version was obtained, with high reliability and good construct validity, similar to the original Canadian PORPUS version. It can therefore be used to measure health-related quality of life and utilities in Spanish prostate cancer patients. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|